There are some articles so important and illuminating that any National Virtual Clinic such as LiverRight must post them anew. We treat Hepatitis, and we’re relentlessly focused on innovation in all forms of Liver Disease.
There’s this July 2022 article The Payer License Agreement, or “Netflix model,” for hepatitis C virus therapies enables universal treatment access, lowers costs and incentivizes innovation and competition by David W Matthews, Samantha Coleman, Homie Razavi, Jean-Manuel Izaret.
And it’s further discussed here, which is the source for the graphic above: Using the Drug Pricing Netflix Model to Help States Tackle the Hep C Crisis from the USC Leonard D. Schaeffer Center for Health Policy & Economics.
Key clip from the article–
“Across the country states are grappling with growing populations with infectious disease, many of which disproportionately affect vulnerable populations who have the least access to care.
Hepatitis C is a particularly egregious example. Twenty-thousand people die from hepatitis C each year; that is more than the combined death toll from 60 other infectious diseases (including HIV) combined. And unlike other public health challenges, there is a cure that has been on the market since 2013.
This duality – a cure for a devastating disease and limited access to it due to a high price tag – were what motivated Neeraj Sood, a professor at the USC Schaeffer Center for Health Policy & Economics and the Price School of Public Policy, to explore innovative payment models as a strategy for government entities to be able to pay for lifesaving cures that could eradicate diseases like hepatitis C.”
=